|Bid||5.13 x 800|
|Ask||5.14 x 800|
|Day's Range||5.12 - 5.28|
|52 Week Range||1.42 - 5.46|
|Beta (5Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19) * Aligos Therapeutics Inc (NASDAQ: ALGS) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * China Biologic Products Holdings Inc (NASDAQ: CBPO) (announced a go-private transaction) * Corcept Therapeutics Incorporated (NASDAQ: CORT) (announced a ruling upholding the validity of all claims of U.S. Patent No. 10,195,214) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * Pacira Biosciences Inc (NASDAQ: PCRX) * Prelude Therapeutics Inc (NASDAQ: PRL) * Replimune Group Inc (NASDAQ: REPL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Spruce Biosciences Inc (NASDAQ: SPRB) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Travere Therapeutics, Inc. (RTRX) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Twist Bioscience Corp (NASDAQ: TWST) * Urovant Sciences Ltd (NASDAQ: UROV) * Veracyte Inc (NASDAQ: VCYT)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 19) * Benitec Biopharma Inc (NASDAQ: BNTC) * Kiromic Biopharma Inc (NASDAQ: KRBP) * Polypid Ltd (NASDAQ: PYPD)Stocks In Focus Amarin's Late-Stage Vascepa Trial In China Meets Study Goals Amarin Corporation plc (NASDAQ: AMRN) announced positive, statistically significant top-line results from a Phase 3 clinical trial of its fish oil pill Vascepa conducted in China by its partner, Edding. The study, which investigated Vascepa as a treatment for patients with very high triglycerides, met its primary efficacy endpoint as defined in the clinical trial protocol and demonstrated a safety profile similar to placebo, the company said.The company said the findings are being prepared to support Edding's dossier for seeking regulatory approval of Vascepa in mainland China.Amarin shares were jumping 18.06% to $5.36 premarket Friday.Mesoblast Strikes Stem Cell Therapy Collaboration Agreement With Novartis Mesoblast limited (NASDAQ: MESO) announced an exclusive worldwide license and collaboration agreement with Novartis AG (NYSE: NVSP) for the development of its mesenchymal stromal cell product remestemcel-L, with an initial focus on the development of the treatment of acute respiratory distress syndrome, including that associated with COVID-19.The agreement provides for Novartis making a $50-million upfront payment, including $25 million in equity. Mesoblast may also receive a total of $505 million pending achievement of precommercialization milestones for ARDS indications. It could also receive additional payments post-commercialization of up to $750 million based on achieving certain sales milestones and tiered double-digit royalties on product sales.Separately, Mesoblast reported first-quarter revenue of $1.3 million, down from $17 million in the year-ago quarter, which included $15 million in upfront milestone payment received for the strategic partnership with Grunenthal GmbH.The net loss per share widened from 1.10 cents to 4.21 cents.The stock jumped 17.73% premarket to $13.88. Lilly's Drug Combo Issued Emergency Use Authorization For COVID-19 Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) said the FDA issued an emergency use authorization for the distribution and emergency use of baricitinib to be used in combination with Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.Baricitinib, discovered by Incyte, has been licensed to Lilly.Separately, Lilly announced a R&D and exclusive license agreement to utilize Precision BioSciences Inc's (NASDAQ: DTIL) proprietary ARCUS genome editing platform for the R&D of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy and two other undisclosed gene targets.Lilly shares were up 0.7% premarket at $144.41, while Gilead shares were down 1.62% at $59.65.Precision BioSciences shares were jumping 28.1% to $12.40 in premarket trading Friday.Pfizer, BioNTech To Submit EUA For Coronavirus Vaccine Friday Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) confirmed that they would submit emergency use application for their coronavirus vaccine candidate to the FDA on Friday.In premarket trading Friday, Pfizer was adding 1.6% to $36.77 and BioNTech shares were rallying 6.99% to $101.57.Related Link: The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The MarketsBeiGene's In-Licensed Osteoporosis Drug Gets Label Expansion In China Beigene Ltd (NASDAQ: BGNE) said the China National Medical Products Administration has approved Xgeva for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma.Developed by Amgen, Inc. (NASDAQ: AMGN) and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, Xgeva is also approved and marketed in China for the treatment of adults and skeletally mature adolescents with giant cell tumor of the bone that is unresectable or where surgical resection is likely to result in severe morbidity.MannKind Gets Final Development Milestone Payment Of $12.5M For Hypertension Drug MannKind Corporation (NASDAQ: MNKD) said it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics Corporation (NASDAQ: UTHR) for the development and commercialization of a dry powder formulation of treprostinil. The fourth milestone payment fetched MannKind $12.5 million.View more earnings on IBBTreprostinil Technosphere is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension."We are looking forward to working with United Therapeutics during the first part of 2021 to prepare an FDA submission for TreT," said MannKind CEO Michael Castagna.In after-hours trading, MannKind shares were up 2.54% to $2.83.AstraZeneca's Imfinzi Approved For Additional Dosage In Lung, Bladder Cancers AstraZeneca plc (NASDAQ: AZN) said its Imfinzi has been approved in the U.S. for an additional dosing option, a 1,500mg fixed dose every four weeks in the approved indications of unresectable Stage 3 non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.In premarket trading Friday, the shares were up 2.07% to $55.15.Aptevo Confirms Takeover Interest For $50/Share In Cash Aptevo Therapeutics Inc (NASDAQ: APVO) confirmed it has received an unsolicited non-binding indication of interest from Tang Capital Partners, LP expressing its interest in acquiring all of the outstanding shares of Aptevo that it does not already own for $50 per share in cash.While recommending that shareholders take no action at this juncture, the company said its board will carefully evaluate and consider this indication of interest in due course in the context of Aptevo's strategic plans, and its ongoing review of a broad range of opportunities to enhance stockholder value.After jumping 29.10% to $45.69 in regular trading on the speculation, the stock was down slightly premarket at $45.65.Affimed Reports Positive Phase 1 Results For Cancer Drug Combo Affimed NV (NASDAQ: AFMD) announced the publication in Blood of positive results for the Phase 1b study of AFM13, a CD30/CD16A innate cell engager, in combination with Merck & Co., Inc.'s (NYSE: MRK) Keytruda.The results demonstrate promising signs of efficacy including an objective response rate of 88% at the highest treatment dose, as well as a complete response of 46% in patients with relapsed/refractory Hodgkin lymphoma. As a monotherapy, Keytruda demonstrated an ORR of 69% and a CR of 22.4% in the KEYNOTE-087 trial.Affimed shares were up 1.66% to $4.90 in after-hours trading.Offerings Avrobio Inc (NASDAQ: AVRO) said it has priced its underwritten public offering of 5 million shares of its common stock at $15 per share for raising gross proceeds of $75 million. The offering is expected to close on or about Nov. 24, subject to customary closing conditions.The stock fell 7.13% to $15.77 in after-hours trading.On The Radar PDUFA Dates Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) has a binary event with respect to its NDA for Lonfarnib in progeria and progeroid laminopathies.Clinical Readout/Presentations 2020 Society for Neuro-Oncology Meeting Presentations: Kazia Therapeutics Ltd (NASDAQ: KZIA): Phase 2 data for GDC-0084 in glioblastoma multiformeConnective Tissue Oncology Society Virtual Annual Meeting Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsEarnings Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. priced its upsized initial public offering of 60 million shares at $27 each, compared to the estimated price range of $24-$27.The shares of the company -- which provides critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases -- will be listed on the Nasdaq under the ticker symbol "MRVI."Sotera Health Company, a global provider of sterilization and lab testing and advisory services to the medical device and pharmaceutical industries, priced its 46.6-million share IPO at $23, the upper end of the estimated price range of $20-$23. The shares of the Broadview Heights, Ohio-based company will be listed on the Nasdaq under the ticker symbol "SHC."Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway * The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Good day, everyone and thank you for standing by, and welcome to Affimed's Third Quarter 2020 Financial Results and Corporate Update Conference Call. The whole team will be available for the Q&A session.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) * Alcon AG (NYSE: ALC) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Aptevo Therapeutics Inc (NASDAQ: APVO) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * BIO-TECHNE Corp (NASDAQ: TECH) * BioLife Solutions Inc (NASDAQ: BLFS) * BioNTech SE - ADR (NASDAQ: BNTX) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE) * C4 Therapeutics Inc (NASDAQ: CCCC) * Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) * Catalent Inc (NYSE: CTLT) * Denali Therapeutics Inc (NASDAQ: DNLI) * Fate Therapeutics Inc (NASDAQ: FATE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Harmony Biosciences Holdings Inc (NASDAQ: HRMY) * Immunovant Inc (NASDAQ: IMVT) * Inspire Medical Systems Inc (NYSE: INSP) * Insulet Corporation (NASDAQ: PODD) * Intellia Therapeutics Inc (NASDAQ: NTLA) (announced dosing of first patient in the CRISPR/Cas9 trial of NTLA-2001 in transthyretin amyloidosis) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * Kodiak Sciences Inc (NASDAQ: KOD) (reacted to its third-quarter results) * Kura Oncology Inc (NASDAQ: KURA) * Kymera Therapeutics Inc (NASDAQ: KYMR) * Larimar Therapeutics Inc (NASDAQ: LRMR) * Merit Medical Systems, Inc. (NASDAQ: MMSI) * Neuronetics Inc (NASDAQ: STIM) * Nevro Corp (NYSE: NVRO) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Pfizer (reacted to its vaccine readout) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * ResMed Inc. (NYSE: RMD) * Silk Road Medical Inc (NASDAQ: SILK) * Shockwave Medical Inc (NASDAQ: SWAV) * Stoke Therapeutics Inc (NASDAQ: STOK) * Sutro Biopharma Inc (NASDAQ: STRO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * West Pharmaceutical Services Inc. (NYSE: WST) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 9) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * Biodesix Inc (NASDAQ: BDSX) * Biogen Inc (NASDAQ: BIIB) (reacted to negative Adcom vote for its Alzheimer's disease drug) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (announced R&D collaboration for development of a standalone, microbiome-based treatment for non-alcoholic steatohepatitis and fibrosis) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Monopar Therapeutics Inc (NASDAQ: MNPR) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Ocuphire Pharma Inc (NASDAQ: OCUP) * Polarityte Inc (NASDAQ: PTE) (reacted to third-quarter results) * Qualigen Therapeutics Inc (NASDAQ: QLGN) * Repro-Med Systems, Inc. (NASDAQ: KRMD)Stocks In Focus Affimed Strikes Licensing Agreement Targeting Multiple Cancers Affimed NV (NASDAQ: AFMD) announced a licensing and strategic collaboration agreement with Roivant Sciences, under which Affimed has granted Roivant the license to the preclinical molecule AFM32. The agreement also allows for the leveraging of Affimed's proprietary, redirected cell-killing platform to generate ICE molecules for oncology against targets not included in Affimed's present pipeline.The agreement provides for Affimed receiving $60 million in upfront consideration, comprised of $40 million in cash and prepaid R&D funding, and $20 million of newly issued shares in Roivant.Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. The company is also eligible to receive up to an additional $2 billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales.Affimed shares were up 13.67% at $4.24 premarket Tuesday. Supernus' ADHD Drug Issued Complete Response Letter, Parkinson's Disease Drug Regulatory Filing Rejected By FDASupernus Pharmaceuticals Inc (NASDAQ: SUPN) said the FDA issued a complete response letter for SPN-812 for the treatment of ADHD in pediatric patients ages 6 to 17. The primary issue cited in the CRL relates to Supernus' in-house laboratory, which conducts analytical testing and recently moved to a new location.The company said it plans to discuss with the FDA the contents of the CRL and clarify to the FDA that the application does not rely solely on this facility for product release. No clinical safety or efficacy issues were identified during the review, Supernus said. Supernus also said it received a refusal-to-file letter from the FDA regarding its NDA for SPN-830 for the continuous treatment of motor fluctuations, or on-off episodes, in Parkinson's disease.In the letter, the FDA requested certain documents and reports to be submitted in support of the application.The company said it plans to seek guidance from the FDA, including a Type A meeting, to discuss the contents of the RTF letter and clarify the steps required for the resubmission of the NDA for SPN-830.The stock was down 19.24% at $20.15 premarket Tuesday. Altimmune Strikes Vaccine Manufacturing Deal With Lonza, Reports Q3 Beat Altimmune Inc (NASDAQ: ALT) said it entered into an agreement with CDMO Lonza for the manufacturing of AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Lonza has facilities in Europe, North America, and South Asia.Separately, Altimmune reported an increase in its third-quarter revenues from $640,000 in 2019 to $2.94 million. Its net loss per share narrowed from 74 cents to 54 cents. Analysts had estimated a loss of 76 cents per share on revenue of $1.05 million.The stock was trading 10.78% higher at $8.68 premarket. Related Link: The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Lilly COVID-19 Antibody Treatment Receives Emergency Use Authorization Eli Lilly And Co (NYSE: LLY) said the FDA has issued emergency use authorization for its investigational neutralizing antibody bamlanivimab 700 mg, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization.View more earnings on IBBLilly said it will begin shipping bamlanivimab immediately to AmerisourceBergen Corp. (NYSE: ABC), a national distributor, which will distribute it as directed by the U.S. government's allocation program.Lilly shares were up 3.28% premarket at $147. Merck To Halt Keytruda-Yervoy Combo Study In Some Lung Cancer Patients Merck & Co., Inc. (NYSE: MRK) said it will stop the KEYNOTE-598 study, a Phase 3 trial investigating Keytruda, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Yervoy, compared with Keytruda monotherapy, for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.Merck attributed the discontinuation to the recommendation of an independent Data Monitoring Committee, which determined the benefit/risk profile of the combination did not support continuing the trial.At an interim analysis, the combination showed no incremental benefit in overall survival or progression-free survival, the study's dual primary endpoints, compared with Keytruda monotherapy, Merck said.Merck shares were up 0.25% at $80.70 premarket. Revance's Drug Flunks Midstage Study In Heel Muscle Inflammation, Biopharma Reports Wider-Than-Expected Loss Revance Therapeutics Inc (NASDAQ: RVNC) announced results from its Phase 2 clinical trial of the investigational drug candidate DaxibotulinumtoxinA for Injection for the management of plantar fasciitis, showing that both the evaluated doses did not met the primary efficacy endpoint of statistically significant improvement from baseline in the NPRS for foot pain at week eight, compared to placebo.Separately, the company reported a wider-than-expected loss for the third quarter.The stock fell 5.80% to $26 in after-hours trading.Arena's Atopic Dermatitis Drug Did Not Meet Primary Endpoint In a Phase 2b Study Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) said the Phase 2b ADVISE clinical trial evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis did not meet the primary endpoint of eczema area and severity index change from baseline at week 12 as compared to placebo.Separately, the company reported a narrower-than-expected loss for the third quarter.The stock ended down 17.66% to $71.98 in after-hours trading.NantKWest Reports Positive Interim Data For COVID-19 Vaccine Nantkwest Inc (NASDAQ: NK) and ImmunityBio, a privately held immunotherapy company, announced positive interim Phase 1 data for their second-generation bivalent, human adenovirus COVID-19 vaccine hAd5.Novavax Appoints CFO, Reports Below-Consensus Q3 Results Novavax, Inc. (NASDAQ: NVAX) announced the appointment of Gregory Covino as CFO. John Trizzino, who previously served as CFO, will now become chief commercial officer while continuing in his role as chief business officer, the company said.Separately, the company reported a third-quarter loss of $3.21 per share on revenue of $157 million. Analysts, on average, were modeling EPS of $1.73 on revenue of $230.56 millionIn premarket trading, the stock was down 5.87% at $85.01. Earnings Fulgent Genetics Inc (NASDAQ: FLGT) said its third-quarter revenue jumped 880% year-over-year to $101.7 million, and non-GAAP net income climbed from 14 cents per share to $2.08 per share.The company raised its full-year revenue guidance.The stock rallied 16.74% to $36.20 in after-hours trading.Neurocrine Biosciences, Inc. (NASDAQ: NBIX) said its third-quarter revenue increased from $222.1 million in 2019 to $258.5 million in 2020. The company's earnings on a non-GAAP basis, increased from 90 cents per share to 97 cents per share.In after-hours trading, the stock plunged 12.5% to $89.96.Offerings TherapeuticsMD Inc (NASDAQ: TXMD) announced an underwritten public offering of its common stock. The company said it intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, and also for working capital and general corporate purposes.The stock slumped 13.16% to $1.32 in after-hours trading.On The Radar Earnings * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (before the market open) * Mediwound Ltd (NASDAQ: MDWD) (before the market open) * Altimmune Inc (NASDAQ: ALT) (before the market open) * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open) * Affimed NV (NASDAQ: AFMD) (before the market open) * Zogenix, Inc. (NASDAQ: ZGNX) (after the close) * 10X Genomics Inc (NASDAQ: TXG) (after the close) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) * Viela Bio Inc (NASDAQ: VIE) (after the close) * CTI BioPharma Corp (NASDAQ: CTIC) (after the close) * Curis, Inc. (NASDAQ: CRIS) (after the close) * Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close) * Eyenovia Inc (NASDAQ: EYEN) (after the close) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close) * Lumos Pharma Inc (NASDAQ: LUMO) (after the close) * Silk Road Medical Inc (NASDAQ: SILK) (after the close) * Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) (after the close) * DermTech Inc (NASDAQ: DMTK) (after the close) * Precision BioSciences Inc (NASDAQ: DTIL) * Passage Bio Inc (NASDAQ: PASG) * Gamida Cell Ltd (NASDAQ: GMDA) * Synthetic Biologics Inc (NYSE: SYN) * Gossamer Bio Inc (NASDAQ: GOSS)Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions * The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.